Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 2023-07, Vol.72 (7), p.2423-2442
• Main Authors: Wang, Shasha, Fan, Guangyu, Li, Lin, He, Yajun, Lou, Ning, Xie, Tongji, Dai, Liyuan, Gao, Ruyun, Yang, Mengwei, Shi, Yuankai, Han, Xiaohong
• Format: Article
• Language: English
• Subjects: Cancer; Cancer Research; Cancer-Associated Fibroblasts - pathology; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - therapy; Cell Adhesion Molecules - genetics; Cytoskeletal Proteins - genetics; Cytoskeletal Proteins - metabolism; Fibroblasts; Humans; Immune checkpoint inhibitors; Immunology; Immunosuppression; Immunotherapy; LIM protein; Lung cancer; Lung Neoplasms - pathology; Medicine; Medicine & Public Health; Metastases; Molecular modelling; Non-small cell lung carcinoma; Nucleotide sequence; Oncology; Phenotypes; Prognosis; Proteomics; Single-Cell Gene Expression Analysis; Small cell lung carcinoma; Transcriptomes; Transcriptomics; Transforming Growth Factor beta - metabolism; Transforming growth factor-b; Tumor microenvironment; Tumor Microenvironment - genetics; Tumorigenesis
• ISSN: 0340-7004; 1432-0851; 1432-0851
• DOI: 10.1007/s00262-023-03428-0

An emerging view regarding cancer-associated fibroblast (CAF) is that it plays a critical role in tumorigenesis and immunosuppression in the tumor microenvironment (TME), but the clinical significance and biological functions of CAFs in non-small cell lung cancer (NSCLC) are still poorly explored. Here, we aimed to identify the CAF-related signature for NSCLC through integrative analyses of bulk and single-cell genomics, transcriptomics, and proteomics profiling. Using CAF marker genes identified in weighted gene co-expression network analysis (WGCNA), we constructed and validated a CAF-based risk model that stratifies patients into two prognostic groups from four independent NSCLC cohorts. The high-score group exhibits a higher abundance of CAFs, decreased immune cell infiltration, increased epithelial–mesenchymal transition (EMT), activated transforming growth factor beta (TGFβ) signaling, and a limited survival rate compared with the low-score group. Considering the immunosuppressive feature in the high-score group, we speculated an inferior clinical response for immunotherapy in these patients, and this association was successfully verified in two NSCLC cohorts treated with immune checkpoint blockades (ICBs). Furthermore, single-cell RNA sequence datasets were used to clarify the molecular mechanisms underlying the aggressive and immunosuppressive phenotype in the high-score group. We found that one of the genes in the risk model, filamin binding LIM protein 1 ( FBLIM1 ), is mainly expressed in fibroblasts and upregulated in CAFs compared to fibroblasts from normal tissue. FBLIM1 -positive CAF subtype was correlated with increased TGFβ expression, higher mesenchymal marker level, and immunosuppressive tumor microenvironment. Finally, we demonstrated that FBLIM1 might serve as a poor prognostic marker for immunotherapy in clinical samples. In conclusion, we identified a novel CAF-based classifier with prognostic value in NSCLC patients and those treated with ICBs. Single-cell transcriptome profiling uncovered FBLIM1 -positive CAFs as an aggressive subtype with a high abundance of TGFβ, EMT, and an immunosuppressive phenotype in NSCLC.